WO2008080009A3 - Neuroprotection by blood flow stabilization - Google Patents

Neuroprotection by blood flow stabilization Download PDF

Info

Publication number
WO2008080009A3
WO2008080009A3 PCT/US2007/088436 US2007088436W WO2008080009A3 WO 2008080009 A3 WO2008080009 A3 WO 2008080009A3 US 2007088436 W US2007088436 W US 2007088436W WO 2008080009 A3 WO2008080009 A3 WO 2008080009A3
Authority
WO
WIPO (PCT)
Prior art keywords
blood flow
neuroprotection
flow stabilization
organs
vasodilators
Prior art date
Application number
PCT/US2007/088436
Other languages
French (fr)
Other versions
WO2008080009A2 (en
Inventor
Susana N Martinez-Conde
Original Assignee
Catholic Healthcare West Dba St Josephs Hospital & Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catholic Healthcare West Dba St Josephs Hospital & Medical Ct filed Critical Catholic Healthcare West Dba St Josephs Hospital & Medical Ct
Priority to CA2674542A priority Critical patent/CA2674542C/en
Priority to EP07855302A priority patent/EP2115106A4/en
Publication of WO2008080009A2 publication Critical patent/WO2008080009A2/en
Publication of WO2008080009A3 publication Critical patent/WO2008080009A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Abstract

A treatment is disclosed for alleviation or prevention of abnormal blood flow to various organs such as the eye, brain, kidneys, heart, feet and other tissues of organs with fine vascular networks that can lead to neurodegeneration as is seen in wet age- related macular degeneration (AMD), epilepsy and diabetes, in which an effective amount of a blood flow regulatory drug is administered to a subject in need of it. Illustrative blood flow regulatory drugs include anticoagulants and vasodilators, and their mixtures.
PCT/US2007/088436 2006-12-21 2007-12-20 Neuroprotection by blood flow stabilization WO2008080009A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2674542A CA2674542C (en) 2006-12-21 2007-12-20 Neuroprotection by blood flow stabilization
EP07855302A EP2115106A4 (en) 2006-12-21 2007-12-20 Neuroprotection by blood flow stabilization

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87635406P 2006-12-21 2006-12-21
US60/876,354 2006-12-21
US97750107P 2007-10-04 2007-10-04
US60/977,501 2007-10-04

Publications (2)

Publication Number Publication Date
WO2008080009A2 WO2008080009A2 (en) 2008-07-03
WO2008080009A3 true WO2008080009A3 (en) 2008-10-09

Family

ID=39563221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/088436 WO2008080009A2 (en) 2006-12-21 2007-12-20 Neuroprotection by blood flow stabilization

Country Status (4)

Country Link
US (1) US20080175831A1 (en)
EP (1) EP2115106A4 (en)
CA (1) CA2674542C (en)
WO (1) WO2008080009A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110189166A1 (en) * 2010-01-29 2011-08-04 John Boucher Methods of treating hemorheologic abnormalities in mammals
US10376183B2 (en) 2014-04-29 2019-08-13 Dignity Health Systems and methods for non-intrusive drug impairment detection
US10743806B2 (en) 2014-06-11 2020-08-18 Dignity Health Systems and methods for non-intrusive deception detection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827832A (en) * 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
US20010041688A1 (en) * 2000-03-13 2001-11-15 Christian Waeber Methods and compositions for the regulation of vasoconstriction
US20040242565A1 (en) * 2001-09-11 2004-12-02 Yoshinori Toshima Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy
US20060194810A1 (en) * 2004-04-30 2006-08-31 Bijan Almassian Methods of treating ischemic related conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827832A (en) * 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
US20010041688A1 (en) * 2000-03-13 2001-11-15 Christian Waeber Methods and compositions for the regulation of vasoconstriction
US20040242565A1 (en) * 2001-09-11 2004-12-02 Yoshinori Toshima Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy
US20060194810A1 (en) * 2004-04-30 2006-08-31 Bijan Almassian Methods of treating ischemic related conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2115106A4 *

Also Published As

Publication number Publication date
WO2008080009A2 (en) 2008-07-03
EP2115106A4 (en) 2010-03-10
CA2674542C (en) 2012-10-09
US20080175831A1 (en) 2008-07-24
CA2674542A1 (en) 2008-07-03
EP2115106A2 (en) 2009-11-11

Similar Documents

Publication Publication Date Title
WO2010014690A3 (en) Medical devices for therapeutic agent delivery
WO2007128817A3 (en) Insulin derivative
WO2012047966A8 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
EP4233861A3 (en) Compositions for treatment of essential tremor
WO2010029441A3 (en) Nasal delivery
WO2008147883A8 (en) Prevention and treatment of complement-associated eye conditions
MY153408A (en) Novel methods
MX2013004699A (en) Pharmaceutical combinations for the treatment of metabolic disorders.
MX337100B (en) Alkoxy compounds for disease treatment.
WO2010129138A3 (en) Phosphorylated and phosphonated pyrone analogs for therapeutic treatment
WO2005105037A3 (en) Use of a viscoelastic composition for treating increased intraocular pressure
MY142036A (en) New quaternized quinuclidine esters
WO2009127974A3 (en) Pharmaceutical formulation for treating cardiovascular disease
WO2009111418A3 (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
WO2008124088A3 (en) Compositions and methods for the treatment of heart failure
WO2008013986A3 (en) Compositions and methods for treating or preventing ophthalmic light toxicity
WO2009116037A3 (en) NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801
WO2007075720A8 (en) Topical mecamylamine formulations for ocular administration and uses thereof
WO2009051217A1 (en) Fentanyl-containing percutaneous absorption preparation
WO2008086452A3 (en) Treatment and prevention of alzheimer's disease
WO2008080009A3 (en) Neuroprotection by blood flow stabilization
EP2106260A4 (en) Insulin sensitisers and methods of treatment
WO2008152507A3 (en) Compositions and methods for treating ophthalmic disorders
WO2008065444A3 (en) Substituted quinazolines
WO2006079625A3 (en) Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07855302

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2674542

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007855302

Country of ref document: EP